- Details
- The DANUBE study was designed as a randomized phase 3 study to investigate durvalumab monotherapy versus durvalumab + tremelimumab versus platinum-based chemotherapy in the first-line setting for patients with unresectable, locally advanced, or metastatic urothelial carcinoma. In this conversation with Alicia Morgans, MD, MPH, Thomas Powles, MD shares results of the phase 3 DANUBE study presented...
|
- Details
- In this conversation with Alicia Morgans, MD, MPH, Ben Tran, MBBS, FRACP, highlights the interim results from a phase 1 study of AMG160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) presented at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress. Biographies: Ben Tran, MBB...
|
- Details
- Petros Grivas, MD, PhD, joins Alicia Morgans, MD, MPH highlighting promising data from a different antibody-drug conjugate called sacituzumab govitecan (IMMU-132). There are a number of ongoing studies where sacituzumab govitecan which is being studied in advanced bladder cancer. Enfortumab vedotin targets Nectin-4, while sacituzumab govitecan is targeting Trop-2. Dr. Grivas highlights the final r...
|
- Details
- In this clinical conversation with Alicia Morgans, MD, MPH, and Joshua Meeks, MD, PhD we hear their clinical perspective combination therapies when treating metastatic urothelial carcinoma. They discuss several studies with recent data from the European Society for Medical Oncology Virtual Congress, (ESMO) 2020 including the KEYNOTE-361 the DANUBE trial, and the IMvigor130 data presented at earlie...
|
- Details
- Following the Presidential Symposium presentation at the European Society of Medical Oncology (ESMO) 2020 Virtual Annual Meeting, Toni Choueiri, MD, joins Alicia Morgans, MD, MPH and discusses the CheckMate—9ER phase III, open-label, international randomized controlled trial among patients with previously untreated, histologically confirmed advanced or metastatic renal cell carcinoma with a clear...
|
